��TV

Latest news

Stay updated with our latest insights and breakthroughs

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Press releases

��TV Therapeutics reports durable clinical responses with first-in-class oral ERAP1 inhibitor GRWD5769 across six solid tumor types

In the media

Our CEO & Co-founder Peter Joyce speaks at Longwood Healthcare Leaders

In the media

The Guardian: Smart drug that strips cancer cells of ‘invisibility cloak’ can shrink tumours by 30%, trial shows

In the media

The Guardian: ‘I was getting ready to say goodbye’: cancer patient’s hope after smart drug success

Feature

A dark horse: The untapped therapeutic potential of ERAP2

Feature

A dark horse: The untapped therapeutic potential of ERAP2

Press releases

��TV Therapeutics appoints Edwin Moses as Chair

Press releases

��TV Therapeutics appoints Edwin Moses as Chair

In the media

��TV attends Downing Street

In the media

WATCH: Targeting disease at the source

In the media

WATCH: Targeting disease at the source

In the media

Our lead oncology asset is nominated for Best Biomedical Product at Prix Galien Bridges Awards, recognizing its potential in advancing cancer therapeutics.

Feature

We won Best Poster at ESMO 2025

Feature

We won Best Poster at ESMO 2025

In the media

��TV Therapeutics wins Biotech of the Year at the Pharma Industry Awards

In the media

��TV x Innovate UK: Making cancer cells visible to the immune system

Press releases

��TV Therapeutics begins dosing of the first ��TV to target the antigenic source of autoimmunity

Press releases

��TV Therapeutics begins dosing of the first ��TV to target the antigenic source of autoimmunity

In the media

BiotechTV interviews Peter Joyce (CEO & Co-founder)

Feature

The dawn of antigen modulation

Feature

The dawn of antigen modulation

Feature

Could antigen modulation address autoimmune diseases?

Feature

Could antigen modulation address autoimmune diseases?

Press releases

��TV Therapeutics presents first clinical data for GRWD5769, a first-in-class ERAP1 Inhibitor, at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting

Press releases

��TV Therapeutics presents first clinical data for GRWD5769, a first-in-class ERAP1 Inhibitor, at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting

Press releases

��TV Therapeutics to Present First Clinical Data for GRWD5769, a First-in-Class ERAP1 Inhibitor, at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting

Press releases

��TV Therapeutics to Present First Clinical Data for GRWD5769, a First-in-Class ERAP1 Inhibitor, at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting

In the media

��TV Therapeutics raises €46 million Series B to develop disease-modifying therapies for autoimmune disorders

Press releases

��TV Therapeutics closes oversubscribed $50m Series B financing expansion, led by ICG Life Sciences Team, to accelerate and expand first-of-its-kind antigen modulation technology

Press releases

��TV Therapeutics closes oversubscribed $50m Series B financing expansion, led by ICG Life Sciences Team, to accelerate and expand first-of-its-kind antigen modulation technology

Press releases

Promising preclinical data reported at AACR 2023

Press releases

Promising preclinical data reported at AACR 2023

Press releases

Announcing the dosing of first patient in our clinical study

Press releases

Announcing the dosing of first patient in our clinical study

In the media

��TV reels in $49M to enter the clinic for new immunotherapy target

Press releases

$49 Million Series B financing oversubscribed

Press releases

$49 Million Series B financing oversubscribed

Press releases

Supply agreement with Regeneron for GRWD5769 clinical trial

Press releases

Supply agreement with Regeneron for GRWD5769 clinical trial

Press releases

Brett Carter joins board of Directors of Australian subsidiary

Press releases

Brett Carter joins board of Directors of Australian subsidiary

Press releases

Formation of our Clinical Advisory Board

Press releases

Formation of our Clinical Advisory Board

Press releases

Preclinical data on first-in-class ERAP1 inhibitors presented at SITC

Press releases

Preclinical data on first-in-class ERAP1 inhibitors presented at SITC

Press releases

£1.1m InnovateUK grant funding to accelerate ERAP1 inhibitor programme

Press releases

£1.1m InnovateUK grant funding to accelerate ERAP1 inhibitor programme

Press releases

£2.5m Series A2 financing for development of therapies targeting ERAP2

Press releases

£2.5m Series A2 financing for development of therapies targeting ERAP2

In the media

��TV bags cash to advance small molecule I-O program

Discover how our therapies are reshaping ��TV for various diseases and conditions.

Harnessing antigen modulation to empower T cells against diseases.